Relieva
Relieva

Relieva

Live
Bio Curated
IPT
Other
$RLV
BASE

Relieva is redefining therapeutic innovation through the world’s first proprietary cannabis and hemp pre-roll blend engineered for targeted pain relief. Leveraging advanced cannabinoid and terpene research, Relieva integrates scientific precision, sustainable production, and blockchain-enabled IP tokenization to establish a new benchmark in functional medicine innovation and therapeutic transparency.

Community Sentiment

How do you feel about this ipt?

...
No trend data
0
Community Size
0%
Growth Rate
Market Details
Project

Market Overview

$4.1 B
US pre-roll cannabis sales in 2024
606%
Infused pre-roll cannabis growth in 2024
$125 B
Global cannabis market by 2030

Additional Documentation

Litepaper
Pitch Deck

Summary

The first tokenization of IP in the cannabis wellness and targeted medicine sector.

Problem

The first proprietary cannabis and hemp derived pre-roll blend designed for pain relief.

Impact

$25m in existing IP, assets and infrastructure to leverage off for the development of the new IP.

Brendan de Kauwe

Brendan is a Financial Services Licence Responsible Manager with global capital markets experience, serving on NASDAQ and ASX boards. Since 2015, he’s led multiple tokenized RWA, DeFi, and blockchain ventures as founder and director.

Simon Owen

Simon is a corporate lawyer and advisor with 30 years’ experience in tech, biotech, fintech, and blockchain. He’s advised nearly 100 capital raisings and co-founded a pioneering blockchain investment firm, advising ventures across legal, regulatory, and strategic matters globally.

Andreas Gedeon

Andreas is a global cannabis industry leader with 10+ years’ experience as CEO and Director. He’s led firms through regulatory challenges, product development, and stock exchange listings across pharma and nutraceutical sectors in emerging and mature markets.

Steve James

Steve has 30+ years in financial services, holding senior roles at major banks and leading FX trading and broking ventures. Now CEO of ASX-listed DomaCom, he’s an experienced director with multiple qualifications in law, markets, governance, and corporate leadership.

Q1 2026

Phase I — Research & Formulation

Identify target outcomes and map active compound combinations

Phase II — Pilot Manufacturing

Produce small batches for lab and sensory testing under regulatory standards

Phase III — IP Protection

File patents and trademarks for novel formulations, processes, and branding

Phase IV — Brand & Regulatory Positioning

Establish compliant wellness product positioning with FDA and other regulators

Q1 2027

Phase V — Market Testing

Soft launch via pilot retail or e-commerce channels to gather consumer insights and early revenues

Tokenomics

10,000,000

Total Supply
Ignition Sale
10%
Wide Liquidity
22.5%
Concentrated Liquidity
15%
Team
10%
Treasury
35%
Bio Protocol Call Option
2.5%
veBIO Airdrop
5%
Wide Liquidity
Concentrated Liquidity
Bio Protocol Call Option
Ignition Sale (80% vesting)
Ignition Sale (20% liquid)
Treasury
veBIO Airdrop
Team
Loading chart...
Community
Feed
...

Stay up to date

Get the latest community updates and find out about upcoming Relieva developments